Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company, Lilly Corporate CenterfiledCriticalEli Lilly And Company
Priority to YU21797ApriorityCriticalpatent/YU21797A/en
Publication of YU21797ApublicationCriticalpatent/YU21797A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Opisana su nova jedinjenja formule I u kojoj R1, R2, R3, R4, R5 i R6 imaju značenja navedena u opisu i patentnim zahtevima, koja su efikasna za tretiranje ili sprečavanje fiziološkog poremećaja izazvanog viškom neuropeptida Y. Takodje je opisano dobijanje jedinjenja gornje formule i njegovo korišćenje za pripremanje farmaceutskih formulacija koje ga sadrže, kao i te farmaceutske formulacije.New compounds of formula I are described in which R1, R2, R3, R4, R5 and R6 have the meanings set forth in the description and claims, which are effective for treating or preventing a physiological disorder caused by excess neuropeptide Y. The preparation of the compounds of the above formula and its use for the preparation of pharmaceutical formulations containing it, as well as those pharmaceutical formulations.
YU21797A1997-05-271997-05-27Benzimidazolyl neuropeptide y receptor antagonists
YU21797A
(en)